शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
VIKASLIFENSEVikas Lifecare Limited· Commercial Services & SuppliesHighNeutral
Announced Wed, 22 Apr, 2026 · 24:14 IST

Q2 FY26 Results: Net Loss of ₹349L; H1 Profit Boosted by One-Time Ebix Settlement

Emphasis of matterResults restatedRelated-party transactionsResults View source PDFExplain this filing

VIKASLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.0%Reaction day
₹1.65
prior close
₹1.68
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.3% vs market
Trading & Distributors peers, median of 134sector+0.1%-0.1% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.6
10m
-1.8
15m
-3.6
30m
-4.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.0+1.3-1.3+0.1-0.1
Next day
-0.6+1.1-1.7+0.0-0.6
2d
-3.0-0.4-2.7-0.4-2.6
3d
-2.4+2.0-4.5-0.4-2.1
4d
-3.0+1.9-4.9-1.0-2.0
5d
-3.6+1.9-5.5-0.7-2.9
1w
-4.8+3.0-7.8-1.9-2.9
15d
-7.3+2.3-9.6-3.3-3.9
1m
-12.1+2.8-15.0-4.6-7.5
2m
-9.7+11.9-21.6-5.4-4.3
3m
-20.6+10.5-31.1-10.8-9.8
UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 134Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2/H1 FY26 unaudited results (ended Sep 30, 2025). Q2 standalone revenue rose to ₹14,097.78L (vs ₹13,035.63L YoY) but posted a net loss of ₹349.41L. H1 net profit of ₹12,414.82L is largely driven by a one-time ~₹13,030L gain from the Ebix UK settlement (51% equity received by VLL after consortium default). Auditor flagged emphasis of matter on pending regulatory approvals for the Ebix transaction, restatement of Q1 FY26 results (turning a loss into a profit), and material related party transactions awaiting shareholder approval. Board also cleared a postal ballot addendum to seek member approval for RPTs and other routine transactions.

Likely market impact

Q2 shows operating loss; H1 profit is one-time settlement, not core business. Auditor flags RPT compliance gaps and prior restatement, raising governance concerns.